Carmeda AB
http://www.carmeda.se
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Carmeda AB
Biocoatings: Not Just the Icing on the Cake
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Stent and Deliver
Stents have been very effective at avoiding elastic recoil by mechanically holding arteries open after balloon angioplasty. They have also, to a certain extent, alleviated the problem of restenosis, the reocclusion of the artery in the months following angioplasty. Unfortunately, however, stents don't go far enough to prevent restenosis--anywhere from 10% to 40% of patients will develop restenosis within six months of revascularization procedures--and the devices frequently result in a new, man-made and difficult-to-treat kind of restenosis, known as in-stent restenosis. Thus, device developers are putting serious development effort into enhanced stents that can carry and deliver drugs to combat restenosis locally.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Biomaterials
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice